Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting , to be held from February 27-March 2, 2026, in Philadelphia, PA.

“ Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress, ” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “ We will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucrictibant for prophylaxis of HAE attacks, and pharmacokinetic data of deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucrictibant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay. ”

Details of the presentations are as follows:

Title: A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema Presenter: Evangelia Pardali, Ph.D. Poster Number: 078 Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST

Title: Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks Presenter: Teresa Caballero, M.D., Ph.D. Poster Number: 154 Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST

Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study Presenter: Michael E. Manning, M.D. Poster Number: 159 Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST

Title: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study Presenter: Marc A. Riedl, M.D., M.S. Featured Poster Number: 831 Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study Presenter: John Anderson, M.D. Featured Poster Number: 832 Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

Title: Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks Presenter: Zhi-Yi Zhang, Ph.D. Featured Poster Number: 834 Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST

The abstracts are available to view in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) at jacionline.org .

The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations .

About Pharvaris Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/ .